Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Trastuzumab Rezetecan and Adebrelimab for HER2-positive Muscle-invasive Bladder Cancer
NCT07624201Phase 2Active, not recruiting
- Sponsor
- Harbin Medical University
- Start
- Jun 2026
- Primary completion
- Jun 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of trastuzumab rezetecan and adebrelimab in muscle-invasive bladder cancer (MIBC), sponsored by Harbin Medical University. Primary endpoint: Pathological Complete Response. Started Jun 2026; status: active, not recruiting.
02
Drugs
trastuzumab rezetecanadebrelimab
03
Conditions
muscle-invasive bladder cancer (MIBC)
Beyond the preview
Go deeper on NCT07624201.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07624201.